Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Oct 21:11:9005-9015.
doi: 10.2147/CMAR.S207677. eCollection 2019.

Berberine induces apoptosis in non-small-cell lung cancer cells by upregulating miR-19a targeting tissue factor

Affiliations

Berberine induces apoptosis in non-small-cell lung cancer cells by upregulating miR-19a targeting tissue factor

Qian-Qian Chen et al. Cancer Manag Res. .

Abstract

Background: Berberine (BBR) from the widely used Chinese herbal medicine Huanglian has an array of pharmacological and biochemical properties, including anti-neoplastic activity. However, the specific mechanisms underlying these properties are unknown. The aim of this study was to explore the anti-tumor mechanisms of BBR in non-small cell lung cancer (NSCLC).

Methods: The effects of BBR on NSCLC tumor development and programmed cell death were investigated both in vivo and in vitro. Luciferase reporter assays were used to determine whether tissue factor (TF) was a target of miR-19a.

Results: BBR suppressed NSCLC growth and promoted apoptosis in NSCLC cells by modulating miR-19a and TF expression. Luciferase assays showed that TF was a direct inhibitory target of miR-19a in NSCLC cells. BBR induced apoptosis through the miR-19a/TF/MAPK axis.

Conclusion: The results suggest that BBR induces apoptosis of NSCLC cells via the miR-19a/TF/MAPK signaling pathway.

Keywords: MAPK; NSCLC; TF; berberine; miR-19a; non-small-cell lung carcinoma; tissue factor.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests in this work.

Figures

Figure 1
Figure 1
Berberine suppresses the invasion, migration and proliferation of NSCLC cells and induces apoptosis in vitro. (A) Berberine inhibits A549 and PC9 cell proliferation. (B) Berberine inhibits colony formation of A549 and PC9 cells. (C) Berberine inhibits A549 and PC9 cell migration. (D) Berberine inhibits A549 and PC9 cell invasion. (E) Flow cytometry was used to quantify early and late apoptosis in A549 and PC9 cells in various concentrations of berberine for 48 h. (F) Western blot analysis was performed to examine the effects of berberine on the expression of apoptosis-related proteins. Mean values of three independent experiments are shown. Values are the mean ± SD, *P<0.01; **P<0.001, compared to vehicle controls (0.008% DMSO).
Figure 2
Figure 2
Berberine inhibits the growth of NSCLC and promotes apoptosis in vivo. (A) Berberine inhibits NSCLC growth in vivo. (B) Tumor weights in berberine and control groups. (D) Weights of mice in berberine and control groups. (E-F) Berberine had inhibitory effects on solid tumor cell proliferation shown by immunohistochemistry of Ki67, bcl-2. Values in each group are expressed as mean ± SD. **P<0.001.
Figure 3
Figure 3
Berberine induces apoptosis by regulating miR-19a in NSCLC. (A) Berberine up-regulates miR19a expression in A549 and Pc9 cells in a dose-dependent manner. (B) qRT-PCR analysis of the miR-19a expression levels in miR-NC and miR-19b inhibitor transfection groups treated with berberine (80μM) for 48 h. (C) Percentage of relative cell viability after berberine treatment following transfection of the miR-19a inhibitor for 48 h. (D) Suppression of miR-19a by berberine treatment results in a significant increase in apoptotic cells. (E) Western blot analysis was performed to demonstrates that berberine induces apoptosis through miR-19a. Mean values of at least three independent experiments are shown. Values are expressed as mean ± SD, *P<0.05; **P<0.001, compared to vehicle controls (0.008% DMSO).
Figure 4
Figure 4
MiR-19a directly targets TF in NSCLC. (A) MiR-19a directly targets TF in the miRBase. (B) Luciferase activity after transfection of F3-WT or F3-MUT with miR-19a-3p mimics or mimics-NC. (C) qRT-PCR analysis of the relative expression of TF in A549 and PC9 cells transfected with miR-19a mimics or miR-19a inhibitors, with or without berberine treatment. (D) Western blot analysis of the relative TF expression in A549 and PC9 cells transfecred with miR-19a mimics or miR-19a inhibitors, with or without berberine treatment. β-Actin was used as a loading control. Values are expressed as mean ± SD, *P<0.05; **P<0.001, compared to vehicle controls (0.008% DMSO).
Figure 5
Figure 5
Berberine induces apoptosis by regulating the miR-19a/TF/MAPK axis in NSCLC. (A) qRT-PCR analysis of TF expression in BEAS-2B, A549, Pc9, H1299 and H460 cell lines. (B) Berberine up-regulates TF expression in A549 and Pc9 cells in a dose-dependent manner. (C) qRT-PCR analysis of TF expression in control and TF overexpression groups ± berberine (80 μM) for 48 h. (D) Percentage of relative cell viability after berberine treatment and TF overexpression for 48 h. (E) Suppression of TF overexpression by berberine significantly increases apoptosis. (F) Western blot analysis was performed to assess the effects of miR-19a on the expression of apoptosis-related proteins in response to berberine. Mean values of at least three independent experiments are shown. Values are expressed as mean ± SD, *P<0.05; **P<0.001, compared with the vehicle control (0.008% DMSO).

References

    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7–30. doi:10.3322/caac.21442 - DOI - PubMed
    1. Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc. 2008;83(5):584–594. doi:10.4065/83.5.584 - DOI - PMC - PubMed
    1. Zou W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer. 2005;5(4):263–274. doi:10.1038/nrc1586 - DOI - PubMed
    1. Inoue A, Yoshida K, Morita S, et al. Characteristics and overall survival of EGFR mutation-positive non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors: a retrospective analysis for 1660 Japanese patients. Jpn J Clin Oncol. 2016;46(5):462–467. doi:10.1093/jjco/hyw014 - DOI - PMC - PubMed
    1. Tang J, Feng Y, Tsao S, Wang N, Curtain R, Wang Y. Berberine and Coptidis rhizoma as novel antineoplastic agents: a review of traditional use and biomedical investigations. J Ethnopharmacol. 2009;126(1):5–17. doi:10.1016/j.jep.2009.08.009 - DOI - PubMed

LinkOut - more resources